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1. Data description {#sec1}
===================

[Table 1](#tbl1){ref-type="table"} presents the description of the dataset, with the list of variables and categories/types of responses. The variables were grouped according to the moment when data were collected: at baseline interview, annual visits on the anniversary of participation, and during the fever episodes. At the baseline interview, the procedures were presented to parents or legal guardians, and an invitation was made for their son/daughter to participate. In the event of agreement on participation, the Informed Consent Form was read and signed. For older children and adolescents their signature of the Assent Form was also collected. The questionnaire contained data on the characteristics of the household, number of people living in the household, number of rooms, and sanitation. A blood sample was drawn from the participating child/adolescent for dengue serology. The family was asked to designate the member that would receive the weekly phone calls for fever surveillance. Beginning in the week after enrolment, this family member started receiving weekly phone calls for fever surveillance. If the participating child/adolescent had fever, a nurse would come to the family\'s home to collect a blood sample for dengue diagnosis, and to fill a questionnaire on dengue signs and symptoms. If the child/adolescent had a dengue diagnosis, a medical appointment was set. During that appointment, an additional blood sample was collected. Every anniversary of their participation they would receive a visit for a blood sample collection, regardless of having had a fever episode during the year.Table 1Description of the dataset, dengue incidence study in Brazil, 2014--2018.Table 1VariablesCategoriesBaseline interviewstudy_idnumericalBirth datedate (dd/mm/yyyy)Census tractCensus Tract CodeInterview datedate (dd/mm/yyyy)AgenumericalSexMale/femaleEnrolled in schoolYes/NoSchool year1 Nursery/2 Preschool/3 Elementary School/4 High School/5 Undergraduate Studies/6 Graduated Studies/99 Not applicableSchool level of head of household1 Nursery/2 Preschool/3 Elementary School/4 High School/5 Undergraduate Studies/6 Graduated Studies/99 Not applicableType of householdHouse/Apartment/Other TypeApartment floornumericalNumber of people in householdnumericalNumber of living roomsnumericalNumber of bedroomsnumericalNumber of kitchensnumericalNumber of bathroomsnumericalLinked to water networkYes/NoWater from wellYes/NoWater from trucksYes/NoWater from riverYes/NoLinked to sewage networkYes/NoGarbage collection destinationPublic Collecting System/Neighborhood Dumpster/Burned/Buried/OtherLaboratory results for baseline and annual serologyBaseline Serology Datedate (dd/mm/yyyy)Baseline Serology resultPositive/Negative/InconclusiveDate of Annual serology - Year1date (dd/mm/yyyy)Result of Annual serology - Year1Positive/Negative/InconclusiveDate of Annual serology - Year2date (dd/mm/yyyy)Result of Annual serology - Year2Positive/Negative/InconclusiveDate of Annual serology - Year3date (dd/mm/yyyy)Result of Annual serology - Year3Positive/Negative/InconclusiveLaboratory results for each fever episodeFever Date Blood Drawdate (dd/mm/yyyy)ELISA IgG ResultPositive/Negative/InconclusiveELISA IgM ResultPositive/Negative/InconclusiveNS1 ResultPositive/Negative/InconclusiveRT PCR ResultPositive/NegativeGenotypeDENV1/DENV2/DENV3/DENV4Confirmed dengue diagnosis1-Yes 0-NoSigns and symptoms for each fever episodeDays of fevernumericalDate of onsetdate (dd/mm/yyyy)Conjunctival injectionYes/NoHeadacheYes/NoAbdominal painYes/NoMyalgiaYes/NoArthralgiaYes/NoChillsYes/NoRetro-orbital painYes/NoCoryzaYes/NoCoughYes/NoSore throatYes/NoDiarrheaYes/NoNauseaYes/NoVomitingYes/NoIntense vomitingYes/NoSomnolenceYes/NoRestlessnessYes/NoBleedingYes/NoRashYes/NoItchingYes/NoLoss of appetiteYes/NoAxillary temperatureNumerical

The dataset contains also some new variables that were created from the original ones, to facilitate the analysis. They are:a)Confirmed dengue case -- 0/1 -- if the participant had a fever episode in which acute dengue was diagnosed.b)DENV 1--0/1 -- for the ones who had an acute dengue diagnosis, if the genotype was dengue virus 1 (DENV1).c)DENV 2--0/1 -- for the ones who had an acute dengue diagnosis, if the genotype was dengue virus 2 (DENV2).d)Asymptomatic dengue infection -- 0/1 -- if the participant had a dengue seroconversion detected in any of the annual serologic surveys, and did not have a fever episode in which the dengue diagnosis was confirmed.e)Final date -- necessary to calculate the follow up time.

[Table 2](#tbl2){ref-type="table"} presents the cohort\'s planned sample size. The data on age-specific incidence of reported cases were used to estimate the sample size, stratified into four age groups (2--5 years of age, 5 to 9, 10 to 13, and 14 to 16).Table 2Planned sample size of the cohort study, stratified by age.Table 2Age stratumSample size2--41.4635--91.01810--1352514--16405Total3.411

Three criteria were applied confirm dengue as the aetiology of the fever episodes. [Table 3](#tbl3){ref-type="table"} presents the distribution of the confirmed cases according to them. The majority of cases were confirmed by the detection of dengue virus RNA by RT-PCR. A small proportion was confirmed by the detection of dengue virus NS1 antigen in serum samples, and just four cases were confirmed by seroconversion of IgM and IgG antibodies.Table 3Distribution of dengue incident cases according to diagnosis criteria.Table 3CriterionNumber%RT -- PCR26786.7NS13712.0IgM and IgG seroconversion41,3Total308100.0

[Table 4](#tbl4){ref-type="table"} presents the frequency of symptoms and signs among the 308 confirmed dengue cases. The more frequently reported symptoms were loss of appetite, myalgia, and abdominal pain. The frequency of warning signs, such as intense vomiting and fluid accumulation was low.Table 4Frequency of signs and symptoms among the confirmed dengue cases, Araraquara, 2014--2018.Table 4Sign/SymptomNumber%Fever308100.0Conjunctival injection12741.2Headache26084.4Abdominal pain16553.6Myalgia18459.7Arthralgia14647.4Chills12540.6Retro-orbital pain12841.6Coryza7022.7Cough7223.4Sore throat8326.9Diarrhea5929.2Nausea14948.4Vomiting11437.0Intense vomiting20.6Somnolence24077.9Restlessness123.9Bleeding82.6Rash7424.0Itching6320.5Loss of appetite21569.8Petechiae5422.0[a](#tbl4fna){ref-type="table-fn"}Tourniquet test positive20.8[a](#tbl4fna){ref-type="table-fn"}Hematocrit \>45%165.2Leukocytes \<30006019.5Platelets \<150,0003812.3Clinical fluid accumulation41.6[a](#tbl4fna){ref-type="table-fn"}Fluid accumulation confirmed by ultrasound31.2[a](#tbl4fna){ref-type="table-fn"}Total308100.0[^1]

2. Experimental design, materials, and methods {#sec2}
==============================================

2.1. Design {#sec2.1}
-----------

In order to overcome the limitations of routine surveillance systems in estimating the burden of dengue \[[@bib1], [@bib2], [@bib3]\] a cohort was set up to determine dengue incidence in children and adolescents from 2 to 16 years of age \[[@bib4]\].

2.2. Site {#sec2.2}
---------

It was conducted in Araraquara (Population 212,617 in 2012), a city located in the central region of the State of São Paulo (21°47′ S; 48°10' W), a location classified as a mid level endemic location for dengue. The first autochtonous dengue case in the city was reported in 1995, and the largest outbreak prior to the period of observation occurred in 2011, when 2500 confirmed dengue cases were reported.

2.3. Period of follow up {#sec2.3}
------------------------

Recruitment of participants was carried out from September 2014 to March 2015. The follow up begun in September 2014 and ended in December 2018.

2.4. Sample size {#sec2.4}
----------------

Dengue incidence in Brazil peaks in young adults \[[@bib6]\] and is low among children. The age-specific incidence of dengue reported cases was used as a reference for the sample size calculation. The planned sample size can be seen in [Table 2](#tbl2){ref-type="table"}.

2.5. Sample selection procedure {#sec2.5}
-------------------------------

A two-stage strategy was used to select the actual participants. In the first stage census tracts were randomly selected. In the selected census tracts the households with children and/or adolescents in the age range of interest were identified. Then, a pre-determined number of children/adolescents was randomly selected.

2.6. Ethical issues {#sec2.6}
-------------------

The protocol was approved by the research ethics review board of the Hospital das Clínicas, of the University of São Paulo\'s Medical School, and is registered at the National Research Ethical Evaluation System, approval number CAAE25706913.6.1001.0065. The parents or legal guardians of the participating children and adolescents provided a signed Informed Consent. Older children and adolescents provided a written Informed assent.

2.7. Procedures {#sec2.7}
---------------

Selected households received a first home visit in which the cohort\'s aims and procedures were presented to the parents or legal guardians, and the invitation to the participation of their son/daughter was made. When they agreed to participate, informed consent and assent were obtained, and a questionnaire was filled, as previously described.

After enrolment, the designated family member received weekly phone calls asking if the child/adolescent has or had a fever during the week. A clinical thermometer was given to the participating family. From the second year on, they could opt for weekly text messages, instead of calls. When the participant reported a fever episode, a nurse would visit the family\'s home to collect a blood sample for acute dengue diagnosis, and fill a questionnaire on the signs and symptoms accompanying the fever. When the dengue diagnosis was confirmed, a medical appointment was scheduled. During that appointment another blood sample was collected. On every anniversary of their participation they received another nurse\'s visit for a blood collection for dengue serology.

2.8. Definitions {#sec2.8}
----------------

*Dengue suspect case*: any fever case, with axillary temperature above 37.5°.

*Symptomatic dengue confirmed case*: a suspect case with at least one of the following criteria fulfilled in acute and/or convalescent serum sample: 1: Detection of dengue RNA by real time polymerase chain reaction (RT-PCR). 2: Detection of NS1 protein. 3: Detection of IgM antibodies with IgG seroconversion. The number of cases confirmed by each criterion is presented in [Table 3](#tbl3){ref-type="table"}. The signs and symptoms presented by the confirmed dengue cases are presented in [Table 4](#tbl4){ref-type="table"}.

*Asymptomatic dengue infections* - Naïve subjects for dengue antibodies at baseline that presented seroconversion (at the one year serology sample) that did not report a febrile episode during the year were considered unapparent dengue infections. The same procedure was applied for those who seroconverted during the four-year follow up.

2.9. Outcomes {#sec2.9}
-------------

The main outcomes of the cohort follow-up were the dengue baseline seroprevalence, the annual seroprevalence, the cumulative incidence and incidence density of symptomatic confirmed dengue cases. Dengue baseline seroprevalence was calculated as the proportion of positive results in the recruitment sample. Yearly seroprevalence was calculated as the proportion of positive results in the yearly serologic surveys. Symptomatic confirmed dengue incidence was calculated as the number of symptomatic confirmed dengue cases divided by the population at risk: in the first year, the number of enrolled participants. For the following years, the number of subjects that participated in the yearly surveys was used as the denominator. Incidence density was calculated as the number of confirmed dengue cases in the numerator divided by the person-time units in the denominator. Asymptomatic dengue infections incidence was calculated as the number of asymptomatic dengue infections divided by the population at risk.

2.10. Laboratory methods {#sec2.10}
------------------------

Dengue IgM and IgG antibodies were tested, using an ELISA assay (DengueVirus IgM Capture DxSelect^**TM**^ and Dengue ELISA IgG, FOCUS Technologies, Cypress, CA, USA), according to the manufacturer instructions.

Blood was drawn in Plasma Preparation Tubes (PPT, Beckton-Dickinson, Brazil) and centrifuged within 4 hours. RNA was extracted from respectively 0.4 mL of plasma on the automated platform iPrep using the PureLink Virus Kit (Life Technologies, Brazil) or 0.5 mL in the NucliSENS Easy-Mag (Biomerieux, Brazil). On both methods, total nucleic acids were eluted into 50uL of buffer.

Extracted nucleic acids were submitted to a one-step dengue generic real-time polymerase chain reaction employing primers and probe previously described \[[@bib7]\] and TaqMan Fast Virus 1-Step Master Mix (ThermoFisher, Brazil). Forty cycles of 95 °C 10 seconds - 60 °C 40 seconds were performed in the thermocyclers models 7300 or 75-00 Fast (Applied Biosystems). Ct values below 37 were considered reactive for dengue RNA. Reactive samples were typed by submitting extracted RNA to four type-specific reactions using the same conditions as above but replacing generic primers/probe by type-specific reagents \[[@bib5]\].

NS1 protein assay was performed by using a commercial kit (Platelia DENV-NS1 Ag, Bio-Rad, Marnes-la- Coquette, France), according to the manufacturer\'s instructions.
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[^1]: Of 245 subjects for whom the data is available.
